Regenxbio (RGNX) Earns News Sentiment Score of 0.19

News stories about Regenxbio (NASDAQ:RGNX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regenxbio earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.5618942127029 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Regenxbio (RGNX) traded up $0.05 during mid-day trading on Tuesday, reaching $26.85. The company had a trading volume of 148,300 shares, compared to its average volume of 416,996. The stock has a market cap of $836.25, a price-to-earnings ratio of -9.94 and a beta of -1.30. Regenxbio has a one year low of $16.30 and a one year high of $36.45.

Several analysts have recently commented on RGNX shares. BidaskClub lowered Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Raymond James Financial restated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. Chardan Capital raised their target price on Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. TheStreet lowered Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Finally, Zacks Investment Research lowered Regenxbio from a “buy” rating to a “hold” rating in a research note on Friday, November 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Regenxbio currently has an average rating of “Buy” and a consensus target price of $40.63.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $30.16, for a total transaction of $150,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of Regenxbio stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $27.33, for a total value of $273,300.00. Following the transaction, the insider now owns 248,530 shares of the company’s stock, valued at approximately $6,792,324.90. The disclosure for this sale can be found here. Insiders sold a total of 84,000 shares of company stock valued at $2,601,996 in the last 90 days. 17.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit